PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies
Cells · 2025
DOI: 10.3390/cells14181422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Sukriti Krishan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales Sydney (UNSW), Sydney, NSW 205…. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Adaptor Proteins, Signal Transducing, N-Myc Proto-Oncogene Protein, Neuroblastoma. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC Project Grant, Cancer Institute NSW Program grant, NHMRC Synergy Grant.
Abstract (Originalsprache)
MYCN and c-MYC are critical driver oncogenes in several childhood cancers, including neuroblastoma. Currently, the clinical development of MYC inhibitors has been hindered by the intrinsically disordered structure of MYC proteins, which lack well-defined ligand-binding pockets. Proliferation-associated protein 2G4 (PA2G4) directly binds to and stabilizes MYCN protein, leading to markedly increased MYCN levels in neuroblastoma cells. Here, we demonstrate that PA2G4 is essential for MYCN-driven tumor growth in neuroblastoma in vivo. Moreover, PA2G4 elevates c-MYC protein levels in neuroblastoma cells by inhibiting its ubiquitin-mediated degradation. In turn, c-MYC upregulates the transcription and protein expression of PA2G4, creating an oncogenic feed-forward expression loop. A small molecule PA2G4 inhibitor, WS6, directly disrupts the PA2G4-c-MYC protein–protein interaction, resulting in decreased levels of both PA2G4 and c-MYC. WS6 exhibited selective cytotoxicity in c-MYC-overexpressing cell lines. Together, these findings identify PA2G4 as a shared cofactor for both the c-MYC and MYCN oncoproteins and highlight its interaction with MYC family oncoproteins as a promising therapeutic vulnerability in MYC-driven cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales Sydney (UNSW), Sydney, NSW 2052, Australia.
- School of Clinical Medicine, UNSW Medicine & Health, University of New South Wales Sydney (UNSW), Sydney, NSW 2052, Australia.
- Olivia Newton-John Cancer Research Institute, Heidelberg, Melbourne, VIC 3086, Australia.
- School of Cancer Medicine, La Trobe University, Heidelberg, Melbourne, VIC 3000, Australia.
- The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, VIC 3050, Australia.
- Department of Medical Biology, University of Melbourne, Parkville, Melbourne, VIC 3010, Australia.
ORCID-Profile: Kenny Yeo, Faith Cheong, Jie-Si Luo, Belamy B Cheung, Glenn M Marshall
Förderung
- NHMRC Project Grant
- Cancer Institute NSW Program grant
- NHMRC Synergy Grant
- Cancer Council NSW Project Grants
- Can Too Foundation
- Tour de Cure Annual Grants
- Perpetual Philanthropic Services
- Kids’ Cancer Project and Neuroblastoma Australia
Zitieren
APA
Krishan, S., Koach, J., Lim, T., Yeo, K., Cheong, F., Luo, J. S., Massudi, H., Gao, X., Heangsarath, S., Kueh, A. J., Herold, M. J., Cheung, B. B., & Marshall, G. M. (2025). PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies. Cells. https://doi.org/10.3390/cells14181422
Vancouver
Krishan S, Koach J, Lim T, Yeo K, Cheong F, Luo JS, et al. PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies. Cells. 2025. doi:10.3390/cells14181422
BibTeX
@article{Krishan2025,
author = {Krishan, Sukriti and Koach, Jessica and Lim, Taylor and Yeo, Kenny and Cheong, Faith and Luo, Jie-Si and Massudi, Hassina and Gao, Xiaomian and Heangsarath, Sopheakwealthy and Kueh, Andrew J and Herold, Marco J and Cheung, Belamy B and Marshall, Glenn M},
title = {PA2G4 Functions as a Cofactor for MYC Family Oncoproteins in MYC-Driven Malignancies},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14181422}
}
EUVIMED